Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) Regulatory Alignment for Predictable and Immediate Device coverage pathway Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development
2026 · 3rd Quarter (July 1 - Sep 30)
EDWARDS LIFESCIENCES LLC
Filed by EDWARDS LIFESCIENCES, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2026
- Income
- Not reported
- Expenses
- $300,000.00
- Registrant
- EDWARDS LIFESCIENCES, LLC
- Client
- EDWARDS LIFESCIENCES LLC
- Filing UUID
- e24bb47f-78d7-4164-806d-ec1c0fbe6b72
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes RAPID) Heart Valve Disease Awareness National Coverage Determination for TAVR Clinical Trials Coverage with Evidence Development
Tariffs
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.